J. David Enloe Jr - Jan 20, 2022 Form 4 Insider Report for Recro Pharma, Inc. (SCTL)

Role: Chief Executive Officer, Director
Signature: By: Ryan D Lake, attorney-in-fact
Stock symbol: SCTL
Transactions as of: Jan 20, 2022
Transactions value $: $0
Form type: 4
Date filed: 1/24/2022, 08:27 PM
Previous filing: Jan 19, 2022
Next filing: Feb 17, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SCTL	Common Stock	Award		+66K	+42.65%		221K	Jan 20, 2022	Direct	F1
transaction	SCTL	Common Stock	Award	$0	+303K	+137.26%	$0.00	524K	Jan 20, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SCTL	Stock Option (Right to Buy)	Award	$0	+442K		$0.00	442K	Jan 20, 2022	Common Stock	442K	$1.65	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On January 20, 2022, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 66,007 performance-based restricted stock units granted in a prior year, which were converted into 66,007 shares of common stock on a one-for-one basis.
F2	These restricted stock units will vest in four equal annual installments beginning on January 20, 2023, subject to continued service with the Company.
F3	The stock option vests in equal monthly installments over 48 months, beginning on February 20, 2022, subject to continued service with the Company.